Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study

Ruffatti, Amelia; Ross, Teresa Del; Ciprian, Manuela; Nuzzo, Monica; Rampudda, Mariaelisa; Bertero, MT; Bergia, Roberta; Caramaschi, Paola; Biasi, Domenico; Capsoni, F.; Montaguti, Luca; Ruffini, R.; Brucato, Antonio; Picillo, U; Fanelli, V.; Riccieri, Valeria; Piccoli, Antônio; Valesini, Guido; Doria, Andrea; Meroni, Pier Luigi; Tincani, Anǵela

doi:10.1136/ard.2008.096669

Cited by 95 publications

(74 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…And as result of a multivariate analysis, hypertension appeared as a risk for arterial thrombosis (Table 5). Ruffatti et al reported hypertension as a risk for the first thrombotic event in aPL carriers by retrospective and prospective cohort studies 16,17 . Previous studies with smaller numbers of patients have also shown the association between hypertension and arterial thrombosis 18,19 .…”

Section: Discussionmentioning

confidence: 99%

Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome

Fujieda

Atsumi

Amengual

et al. 2012

Lupus

View full text Add to dashboard Cite

Objective:To study the clinical and immunological manifestations of the antiphospholipid syndrome (APS) in Japanese population by a single center registration. Methods:In this retrospective cohort study, 141 consecutive patients with APS, fulfilling the Sydney revised Sapporo criteria for definite APS, who visited to our Autoimmune Clinic from 1988 to 2010 were recruited and followed up. All the patients were interviewed and underwent a general physical examination by qualified rheumatologists on the day of blood sampling. Results:The population comprised 119 woman and 22 men with a mean age at diagnosis of 44 years (range 11-83 years). Seventy patients

show abstract

Section: Discussionmentioning

confidence: 99%

Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome

Fujieda

Atsumi

Amengual

et al. 2012

Lupus

View full text Add to dashboard Cite

show abstract

“…The ultimate goal is to accurately predict the risk of APS manifestations based on the laboratory detection and evaluation of antiphospholipid antibodies. Until precise characterization of pathogenic aPLs and methods of their detection become available, the clinical significance of aPLs could only be assessed using aPL determinations in the large patient populations [16][17][18][19]. The same applies to the relative clinical significance of different in-house methods and commercially available kits for aPL determination.…”

Section: Introductionmentioning

confidence: 99%

Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome

Moerloose

Reber

Musiał

et al. 2010

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Summary. Background: Anticardiolipin (aCL) and anti‐β2glycoprotein I (aβ2GPI) antibodies are part of the criteria for antiphospholipid syndrome (APS). Therefore they are widely measured and about 30 commercial kits are available. Objectives: To investigate the analytical and clinical performances of four fully automated, chemiluminescent assays: HemosIL AcuStar aCL IgG, HemosIL AcuStar aCL IgM, HemosIL AcuStar aβ2GPI IgG, and HemosIL AcuStar aβ2GPI IgM. Methods: Cut‐off values were assessed by testing 250 blood donors. Total coefficients of variation (CV) were determined with six plasma pools and two controls ranging from 4.3 to 2694 U mL−1 depending on the assay. Samples from 218 well‐characterized patients and 103 controls were measured in three laboratories to determine inter‐laboratory variation. The results of the 321 samples were compared with three commercial assays (REAADS, INOVA and VARELISA). Results: Cut‐off values were assigned to 20 arbitrary units for all the tests. Total CV ranged from 4.3 to 11.2%. No interference of hemoglobin, bilirubin, triglycerides, heparins and rheumatoid factor was observed. Inter‐laboratory variability was low and no sample changed status. Overall status agreement between HemosIL assays and the comparator kits ranged from 82 to 96%. Sensitivity, specificity, agreement when predicting APS and the odds ratios when predicting a thrombotic or obstetric event gave comparable results between HemosIL AcuStar and the three other assays. Conclusions: Our study demonstrates that the fully automated HemosIL AcuStar aPL assay panel showed similar performances to the three commercial ELISAs commonly used by various laboratories to detect antiphospholipid antibodies.

show abstract

“…Wahl et al (110) suggested that primary prophylaxis with LDA is beneficial in SLE patients, particularly those with aPL. However, not all studies found a protective effect of LDA against first thrombosis (111)(112)(113), and it is important to note that the only randomized, double-blind, placebo-controlled trial investigating the role of LDA in persistently aPL-positive patients (~60% SLE) with no history of thrombosis demonstrated that LDA is not superior to placebo (111).…”

Section: First Thrombosis Preventionmentioning

confidence: 99%

Untitled

2016

Eur J Rheumatol

View full text Add to dashboard Cite

Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study

Abstract: Hypertension or medium/high titres of IgG aCL are risk factors for a first thrombotic event in asymptomatic aPL carriers and primary prophylaxis is protective.

Cited by 95 publications

References 13 publications

Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome

Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome

Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome

Untitled

Contact Info

Product

Resources

About